Cubist Systematic Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-29,923
| Closed | -$13M | – | 4100 |
|
|
2024
Q1 | $12.5M | Buy |
29,923
+5,469
| +22% | +$2.31M | 0.07% | 379 |
|
|
2023
Q4 | $9.95M | Sell |
24,454
-5,807
| -19% | -$2.15M | 0.06% | 453 |
|
|
2023
Q3 | $10.5M | Sell |
30,261
-1,004
| -3% | -$351K | 0.08% | 358 |
|
|
2023
Q2 | $11M | Buy |
31,265
+18,016
| +136% | +$6.07M | 0.07% | 391 |
|
|
2023
Q1 | $4.17M | Sell |
13,249
-81,146
| -86% | -$24.3M | 0.03% | 1081 |
|
|
2022
Q4 | $27.3M | Buy |
94,395
+8,404
| +10% | +$2.56M | 0.16% | 64 |
|
|
2022
Q3 | $24.9M | Buy |
85,991
+10,501
| +14% | +$3.02M | 0.14% | 99 |
|
|
2022
Q2 | $21.3M | Sell |
75,490
-11,084
| -13% | -$2.97M | 0.13% | 115 |
|
|
2022
Q1 | $22.6M | Buy |
86,574
+54,686
| +171% | +$13M | 0.19% | 43 |
|
|
2021
Q4 | $7M | Sell |
31,888
-5,921
| -16% | -$1.15M | 0.07% | 438 |
|
|
2021
Q3 | $6.86M | Sell |
37,809
-54,190
| -59% | -$10.6M | 0.09% | 314 |
|
|
2021
Q2 | $18.6M | Sell |
91,999
-44,859
| -33% | -$9.38M | 0.21% | 63 |
|
|
2021
Q1 | $29.4M | Buy |
136,858
+115,145
| +530% | +$25.3M | 0.38% | 13 |
|
|
2020
Q4 | $5.13M | Sell |
21,713
-7,909
| -27% | -$1.81M | 0.07% | 432 |
|
|
2020
Q3 | $8.06M | Buy |
29,622
+21,307
| +256% | +$5.88M | 0.12% | 214 |
|
|
2020
Q2 | $2.41M | Buy |
8,315
+6,088
| +273% | +$1.65M | 0.04% | 676 |
|
|
2020
Q1 | $530K | Sell |
2,227
-69,391
| -97% | -$15.9M | 0.01% | 1220 |
|
|
2019
Q4 | $15.7M | Buy |
71,618
+61,975
| +643% | +$12.5M | 0.29% | 42 |
|
|
2019
Q3 | $1.63M | Buy |
9,643
+5,598
| +138% | +$990K | 0.03% | 720 |
|
|
2019
Q2 | $742K | Sell |
4,045
-19,566
| -83% | -$3.42M | 0.01% | 1211 |
|
|
2019
Q1 | $4.34M | Buy |
23,611
+4,927
| +26% | +$910K | 0.14% | 173 |
|
|
2018
Q4 | $3.1M | Buy |
18,684
+11,849
| +173% | +$2.05M | 0.15% | 137 |
|
|
2018
Q3 | $1.32M | Sell |
6,835
-40,408
| -86% | -$7.2M | 0.07% | 350 |
|
|
2018
Q2 | $8.03M | Buy |
47,243
+42,349
| +865% | +$6.56M | 0.4% | 20 |
|
|
2018
Q1 | $798K | Buy |
4,894
+2,553
| +109% | +$417K | 0.05% | 549 |
|
|
2017
Q4 | $351K | Sell |
2,341
-15,957
| -87% | -$2.36M | 0.02% | 1139 |
|
|
2017
Q3 | $2.78M | Sell |
18,298
-13,541
| -43% | -$2.04M | 0.16% | 105 |
|
|
2017
Q2 | $4.1M | Buy |
31,839
+27,578
| +647% | +$3.32M | 0.26% | 61 |
|
|
2017
Q1 | $466K | Sell |
4,261
-10,858
| -72% | -$956K | 0.03% | 677 |
|
|
2016
Q4 | $1.11M | Buy |
15,119
+82
| +0.5% | +$6.67K | 0.09% | 330 |
|
|
2016
Q3 | $1.31M | Buy |
15,037
+7,947
| +112% | +$751K | 0.08% | 323 |
|
|
2016
Q2 | $610K | Sell |
7,090
-123,504
| -95% | -$10.7M | 0.04% | 655 |
|
|
2016
Q1 | $10.4M | Buy |
130,594
+84,632
| +184% | +$7.66M | 0.59% | 8 |
|
|
2015
Q4 | $5.78M | Buy |
45,962
+33,683
| +274% | +$4.07M | 0.34% | 33 |
|
|
2015
Q3 | $1.28M | Sell |
12,279
-25,464
| -67% | -$3.27M | 0.06% | 440 |
|
|
2015
Q2 | $4.66M | Sell |
37,743
-47,719
| -56% | -$6.01M | 0.23% | 77 |
|
|
2015
Q1 | $10.1M | Buy |
85,462
+54,657
| +177% | +$6.55M | 0.49% | 7 |
|
|
2014
Q4 | $3.66M | Buy |
+30,805
| New | +$3.47M | 0.2% | 94 |
|
|
2014
Q3 | – | Sell |
-16,995
| Closed | -$1.61M | – | 1889 |
|
|
2014
Q2 | $1.61M | Buy |
+16,995
| New | +$1.19M | 0.1% | 297 |
|
Other funds holding VRTX
Cubist Systematic Strategies's VRTX Position: Q2 2024 in Review
Cubist Systematic Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 29,923 shares — an estimated $13M sold.
Cubist Systematic Strategies first reported a position in VRTX in Q2 2014 and held it in 39 quarters. The position peaked at $29.4M in Q1 2021. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.
- Cubist Systematic Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Cubist Systematic Strategies sold 29,923 Vertex Pharmaceuticals shares in Q2 2024, an estimated $13M.
- Cubist Systematic Strategies first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 39 quarters.
- Cubist Systematic Strategies's Vertex Pharmaceuticals position peaked at $29.4M in Q1 2021.
- 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.
Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.